drugset / Trial / NCT02199743

Lurasidone Effects on Tissue Glutamate in Schizophrenia

NCT02199743

RandomizedParallel-groupQuadruple-blindTreatment

Summary

24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.

Timeline

Start
2013-02
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 8 mg Oral
Comparator Lurasidone Small molecule 80 mg Oral
Comparator Perphenazine Small molecule 32 mg Oral